Description

2-(10-(5-Chlorofuran-2-Yl)-1,3-Dimethyl-2,4-Dioxo-1,3,4,7,8,10-Hexahydro-2H-Pyrimido[4',5':3,4]Pyrrolo[2,1-C][1,4]Thiazin-5-Yl)Thiazole-4-Carboxylicacid is a sophisticated heterocyclic compound designed for advanced research and development. This high-purity intermediate is critical for pharmaceutical chemists exploring novel therapeutic agents, particularly in the areas of kinase inhibition and targeted oncology. It serves as a key building block for medicinal chemistry programs requiring complex fused-ring systems with specific electronic and steric properties.

Application

• Pharmaceutical Intermediate: Primary use as a critical precursor in the synthesis of novel small-molecule drug candidates, especially for kinase-targeted therapies.
• Medicinal Chemistry Research: Enables structure-activity relationship (SAR) studies and lead optimization in drug discovery pipelines.
• Chemical Biology Probes: Serves as a core scaffold for developing selective enzyme inhibitors and molecular probes to study biological pathways.
• Contract Research & Development (CRO/CMO): Supplied to research organizations specializing in custom synthesis and process development for client projects.
• Academic Research: Used in university and institutional labs for fundamental studies on heterocyclic chemistry and new synthetic methodologies.

Basic Information

Product Name	2-(10-(5-Chlorofuran-2-Yl)-1,3-Dimethyl-2,4-Dioxo-1,3,4,7,8,10-Hexahydro-2H-Pyrimido[4',5':3,4]Pyrrolo[2,1-C][1,4]Thiazin-5-Yl)Thiazole-4-Carboxylicacid
CAS No.	1614250-83-7
Molecular Formula	C20H14ClN5O5S2
Molecular Weight	511.94 g/mol
Synonyms	2-[10-(5-Chloro-2-furanyl)-1,3-dimethyl-2,4-dioxo-7,8-dihydro-1H,3H,4H,10H-pyrimido[4',5':3,4]pyrrolo[2,1-c][1,4]thiazin-5-yl]-1,3-thiazole-4-carboxylic acid; 2-(10-(5-Chlorofuran-2-yl)-1,3-dimethyl-2,4-dioxo-1,3,4,7,8,10-hexahydro-2H-pyrimido[4',5':3,4]pyrrolo[2,1-c][1,4]thiazin-5-yl)thiazole-4-carboxylic acid; CAS 1614250-83-7; Fused Pyrimidopyrrolothiazine Derivative; Chlorofuranyl Thiazole Carboxylic Acid Intermediate
EINECS	Contact for details

Quality Control

Our production of this advanced pharmaceutical intermediate adheres to strict quality management systems. Every batch is characterized and tested using advanced analytical techniques including HPLC, NMR, and LC-MS to ensure identity, purity, and consistency. A comprehensive Certificate of Analysis (COA) is provided with each shipment, detailing all critical quality attributes. We support development under cGMP guidelines where required for pre-clinical and clinical stage materials.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). The compound may be hygroscopic (moisture-sensitive); keep the container tightly sealed in a dry environment. For long-term storage, consider storing under an inert atmosphere.

Specification

Item	Specification
Appearance	Off-white to light yellow solid
Identification (HPLC)	Conforms
Identification (NMR)	Conforms
Purity (HPLC)	≥ 95.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.5%
Single Unknown Impurity (HPLC)	≤ 1.0%
Total Impurities (HPLC)	≤ 5.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.